Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
Similar Posts
AMD upgraded to outperform
The “Halftime Report” traders debate a bullish call on AMD by Bernstein analyst Stacy Rasgon.
A point-of-sale system like Square on steroids
A New York City cowboy boot store may sell classic styles, but it’s been improving its sales by using technology and analytics on the Bindo POS iPad app.
Jim Cramer’s guide to investing: Pay attention to big insider buying
CNBC’s Jim Cramer said investors should usually wait until high-quality stocks have had a pullback before buying. But sometimes it’s worth buying some stock at the top, especially if a company engages in significant insider buying. Not to be confused with insider trading, insider buying is based on public information and occurs when executives buy…
Watch CNBC’s full interview with Trivariate Research’s Adam Parker and Wealth Enhancement’s Nicole Webb
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Trivariate Research CEO Adam Parker and Nicole Webb, senior vice president and financial advisor at Wealth Enhancement Group, join ‘Closing Bell’ to discuss their market outlook for 2024, expectations from the Fed, and more. 19:36 Tue, Jan 9 20243:35 PM EST
Options traders betting Nike’s post earnings move has some real sole
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Fast Money Mike Khouw, Optimize Advisors president, joins CNBC’s Melissa Lee and the Options Action traders to talk Nike. 01:52 Wed, Sep 27 20236:10 PM EDT
Watch CNBC’s full interview with Gabelli Funds’ Tony Bancroft and Crutchfield + Partners’ Dean Crutchfield
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Dean Crutchfield, CEO of the crisis management firm Crutchfield + Partners, and Tony Bancroft, portfolio manager at Gabelli Funds, join ‘Power Lunch’ to discuss the continued market fallout for Boeing following a plane’s parts malfunction. 11:57 Wed, Jan 10 20242:27 PM EST
